Citigroup’s Madrigal Pharmaceuticals MDGL Stock Holding History

Citigroup’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.7M	Buy	30,000 +7,500	+33%	+$3.58M	0.01%	1206
2025 Q4	$13.1M	Sell	22,500 -4,500	-17%	-$2.3M	0.01%	1357
2025 Q3	$12.4M	Buy	27,000 +500	+2%	+$187K	0.01%	1347
2025 Q2	$8.02M	Sell	26,500 -13,500	-34%	-$4.02M	﹤0.01%	1534
2025 Q1	$13.2M	Buy	40,000 +27,200	+213%	+$8.94M	0.01%	1193
2024 Q4	$3.95M	Sell	12,800 -5,300	-29%	-$1.49M	﹤0.01%	2197
2024 Q3	$3.84M	Buy	18,100 +2,000	+12%	+$512K	﹤0.01%	2074
2024 Q2	$4.51M	Buy	+16,100	New	+$3.83M	﹤0.01%	1704
2022 Q3	–	Sell	-17,900	Closed	-$1.28M	–	6125
2022 Q2	$1.28M	Buy	+17,900	New	+$1.32M	﹤0.01%	2425

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's MDGL Position: Q1 2026 in Review

Citigroup increased its Madrigal Pharmaceuticals (MDGL) stake by 9.7% in Q1 2026, buying an estimated $1.08M and bringing the position to 25,589 shares worth $13.4M. The position accounts for 0.01% of the portfolio, ranked #1294.

Citigroup first reported a position in MDGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $30.3M in Q4 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Citigroup held 25,589 shares of Madrigal Pharmaceuticals worth $13.4M as of Q1 2026.
Citigroup bought 2,262 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
Madrigal Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #1294 holding.
Citigroup first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
Citigroup's Madrigal Pharmaceuticals position peaked at $30.3M in Q4 2024.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.